参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Uterine Neoplasms Version 2.2019— December 17, 2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed., 2017).
3.Fader AN, Roque DM, Siegel E, et al.Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.J Clin Oncol 2018:JCO2017765966.
4.Watkins JC, Yang EJ, Muto MG, et al.Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome.Int J Gynecol Pathol 2017, 36:115-127.
5.Rose PG, Ali S, Moslemi-Kebria M, et al.Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.Int J Gynecol Cancer 2017, 27:452-458.
6.Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, et al.High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer:Systematic Review and Meta-Analysis of the Literature.J Nucl Med 2016, 57:879-885.
7.Holloway RW, Abu-Rustum NR, Backes FJ, et al.Sentinel lymph node mapping and staging in endometrial cancer:A Society of Gynecologic Oncology literature review with consensus recommendations.Gynecol Oncol 2017, 146:405-415.
8.Ott PA, Bang YJ, Berton-Rigaud D, et al.Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer:Results From the KEYNOTE-028 Study.J Clin Oncol 2017, 35:2535-2541.
9.Paley PJ, Veljovich DS, Press JZ, et al.A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging.Am J Obstet Gynecol 2016, 215:117 e111-117.
10.Soliman PT, Westin SN, Dioun S, et al.A prospective validation study of sentinel lymph node mapping for highrisk endometrial cancer.Gynecol Oncol 2017, 146:234-239.
11.Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017, 357:409-413.(https://www.daowen.com)
12.Ruscito I, Gasparri ML, Braicu EI, et al.Sentinel Node Mapping in Cervical and Endometrial Cancer:Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.Ann Surg Oncol 2016, 23:3749-3756.
13.Rossi EC, Kowalski LD, Scalici J, et al.A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial):a multicentre, prospective, cohort study.Lancet Oncol 2017, 18:384-392.
14.Monterossi G, Ghezzi F, Vizza E, et al.Minimally Invasive Approach in Type II Endometrial Cancer:Is It Wise and Safe? J Minim Invasive Gynecol 2017, 24:438-445.
15.Bodurtha Smith AJ, Fader AN, Tanner EJ.Sentinel lymph node assessment in endometrial cancer:a systematic review and metaanalysis.Am J Obstet Gynecol 2016.
16.Plante M, Stanleigh J, Renaud MC, et al.Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer:Does adjuvant treatment matter? Gynecol Oncol 2017, 146:240-246.
17.Salehi S, Avall-Lundqvist E, Legerstam B, et al.Robotassisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer:A randomised controlled trial.Eur J Cancer 2017, 79:81-89.
18.Schiavone MB, Zivanovic O, Zhou Q, et al.Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.Ann Surg Oncol 2016, 23:196-202.
19.Janda M, Gebski V, Davies LC, et al.Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer:A Randomized Clinical Trial.JAMA 2017, 317:1224-1233.
20.Cancer Facts and Figures 2017.Atlanta, GA:American Cancer Society.
21.Salani R, Khanna N, Frimer M, et al.An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies:Society of Gynecologic Oncology (SGO) recommendations.Gynecol Oncol 2017, 146:3-10.
22.St Clair CM, Eriksson AG, Ducie JA, et al.Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma.Ann Surg Oncol 2016, 23:1653-1659.